Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii

• Status: Unknown status
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

In Siriraj Hospital, Colistin alone for treatment of MDR. A.baumanii or P.aeruginosa contributed to mortality 45%. In vitro studies revealed synergism of Rifampicin and Colistin.

In this study, patients with documented MDR. P.aeruginosa or A.baumanii will be allocated to receive Colistin alone and another group will receive Colistin plus Rifampicin.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mahidol University
• Treatments: Colistin; Rifampin

Criteria

Inclusion Criteria:

• Age>18 years

• Hospitalized to Siriraj Hospital

• Infection with MDR A.baumanii or P.aeruginosa

• Nescessary for treatment with Colistin

• Patient agrees to participate by giving written informed consent.

Exclusion Criteria:

• pregnancy or lactating mother

• Colistin or Rifampicin allergy

• Active hepatic disease or abnormal liver function test

• patient who suspected infection with mycobacterium tuberculosis

• patient who can not drug by enteral feeding